Stock Taper
SCREENER COMPARE ANY 2 STOCKS
VERU
VERU INC.
NASDAQ
$2.63
▼ DOWN 4.20% (-0.12)

KEY STATISTICS

Market Cap$42.13 M
52w High$7.33
52w Low$2.05
Dividend Yield0.37%
FrequencyQuarterly
P/E-4.10
Volume91.06K
Shares Out.16.05M

COMPANY

LEADERSHIP

Mitchell S. Steiner
CHIEF EXECUTIVE
Mitchell S. Steiner

COMPENSATION 2026

Salary$836,211
Stock Awards$0
Incentive Plan Pay$636,156
All Other Comp.$14,000
Total$1,649,663

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 11, 1999
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
20

PRICE TARGET

Target High$5.00
Target Low$3.00
Target Median$4.00
Target Consensus$4.00

UPCOMING EARNINGS

DateNov 26, 2026
DayThursday
Rev. Est.—
NOV
26
THU

SPLIT RECORD

DATETYPERATIO
2025-08-11Reverse1:10

PRICE

$2.63 ▼ DOWN 4.20% (−$0.12)
OVERLAYS
$2.64$2.68$2.729:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM2.63

About Veru Inc.

https://www.verupharma.com ↗

Veru Inc. is a Miami-based biopharma company developing cancer treatments and commercial products like FC2 female condoms, with drug candidates in various clinical trial phases for cancers, COVID-19, and other conditions.

INDUSTRY

Biotechnology

A PRODUCT VERU INC. IS KNOWN FOR

Enobosarm
Enobosarm

Enobosarm is a late-stage oral SARM developed to be combined with GLP-1 drugs to improve weight loss by preserving muscle mass and physical function while promoting fat reduction.

COMPETITORS

COMPETITOR
ARVN COMPARE
LLY COMPARE
REGN COMPARE
RLAY COMPARE

Revenue by Products

IconPRODUCTQ1-2021Q2-2023Q3-2023Q4-2023
Preboost Segment$862.83K — — —
Other Products— $5.52K -$225 ▼$7.72K ▲

Revenue by Geography

MapREGIONQ3-2023Q1-2024Q2-2024Q3-2024
Other Geographical Areas— — — $1.53M
U$1.45M — — —
MOZAMBIQUE— — — $1.32M
UNITED STATES— — — $1.11M
Other Countries$1.28M $784.64K ▼$865.11K ▲—
Z$612K — — —

ETFS HOLDING THIS STOCK

ETFS HOLDING
13
LISTED HERE
2
RANKED BY POSITION SIZE
VTI
0.00% · 531.9K
IWC
0.01% · 50.2K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
80.98%
HOLDERS
113
TOP 12 OF 113 · RANKED BY POSITION SIZE
Blackrock Inc.
7.7M sh · $6.44M
Pvg Asset Management Corp
1.6M sh · $958.44K
Alyeska Investment Group, L.P.
1.0M sh · $2.21M
Potomac Capital Management, Inc.
654.0K sh · $470.88K
Vanguard Group Inc
640.7K sh · $2.43M
Advisor Group Holdings, Inc.
235.8K sh · $113.17K
Millennium Management LLC
231.6K sh · $880.09K
Oppenheimer & Co Inc
210.8K sh · $659.94K
Gsa Capital Partners Llp
195.7K sh · $419K
Geode Capital Management, LLC
184.6K sh · $408.12K
Nuveen Asset Management, LLC
178.6K sh · $116.15K
Blackrock, Inc.
167.1K sh · $522.97K

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF SCIENTIFIC OFFICER
BARNETTE K GARY
Purchase · 1.8K shares
2026-08-13
★
DIRECTOR, OFFICER: PRESIDENT AND CEO
STEINER MITCHELL SHUSTER
Purchase · 604.0K shares
2026-05-04
★
OFFICER: CHIEF ADMIN OFFICER AND CFO
Greco Michele
Purchase · 164.0K shares
2026-05-04
★
DIRECTOR
Katzovitz Loren Mark
Purchase · 102.0K shares
2026-05-04

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
OUTPERFORM 1
2 GRADES IN THE LAST 12 MONTHS
Canaccord Genuity BUY Oppenheimer OUTPERFORM

SECTORS PEERS

PEERPRICE
PYPD$5.07COMPARE
RNXT$1.67COMPARE
ANVS$1.72COMPARE
CELU$1.58COMPARE
DYAI$0.61COMPARE
RVPH$0.52COMPARE
BTAI$0.18COMPARE
BCAB$1.74COMPARE